TABLE 2.
Risk factors for SRE
| Univariate analysis | |||||
|---|---|---|---|---|---|
| Variables | SRE− | SRE+ | 95% C.I./Odds raio | p‐value | |
| Age |
<65 ≥65 |
19 45 |
3 8 |
0.27‐4.71 1.13 |
1.0000 |
| Sex |
male female |
31 33 |
7 4 |
0.14‐2.01 0.54 |
0.5161 |
| Previous BP treatment |
no yes |
51 13 |
8 3 |
0.34‐6.33 1.47 |
0.6922 |
| Bone scale |
0, 1 2, 3 |
12 52 |
1 10 |
0.93‐17.30 4.00 |
0.1009 |
| History of DM |
no yes |
52 12 |
6 5 |
0.94‐13.83 3.61 |
0.1110 |
| History of SRE |
no yes |
35 29 |
6 5 |
1.25‐24.43 1.01 |
1.0000 |
| PS (ECOG) |
0, 1, 2 3, 4 |
54 10 |
6 5 |
1.15‐17.63 4.50 |
0.0370 |
| AL amyloidosis |
no yes |
63 1 |
8 3 |
2.19‐255.21 23.63 |
0.0090 |
| Multivariate analysis | ||||
|---|---|---|---|---|
| Variables | 95% C.I. | Odds ratio | p‐value | |
| PS (ECOG) | 3, 4 | 0.58 – 12.90 | 2.74 | 0.2030 |
| AL amyloidosis | yes | 1.20 – 177.50 | 14.62 | 0.0352 |
BP, bisphosphonate; CI, confidence interval; DM, diabetes mellitus; ECOG, Eastern Cooperative Oncology Group; PS, performance status.